PL EN


Preferences help
enabled [disable] Abstract
Number of results
2004 | 64 | 1 | 99-105
Article title

Alzheimer's disease and acetylcholine receptors

Selected contents from this journal
Title variants
Languages of publication
EN
Abstracts
EN
Cholinergic abnormalities, alongside senile plaques, neurofibrillary tangles, and extensive neuronal loss, are the major characteristics in Alzheimer's disease (AD). Both nicotinic and muscarinic acetylcholine receptors are decreased in AD, and it has been shown that the reduction in the number of acetylcholine receptors precedes other pathologic changes. Anti-cholinergic drugs induce amnesia, which can be reversed by withdrawal of the medication. Inhibition of the down-regulation of acetylcholine is, therefore, a strategy for the treatment of AD because it could augment acetylcholine levels within synaptic clefts. In this context, acetylcholinesterase inhibitors, which improve cognitive functions, are currently approved for the treatment of AD. Stimulation of acetylcholine receptors, nicotinic or muscarinic, is another strategy; some drugs are currently under investigation, and reported to be effective. In addition, nicotinic stimulation exerts a neuroprotective effect, and reduces the amyloid burden. Cholinergic therapy may counter the symptoms and progress of AD.
Keywords
Publisher

Year
Volume
64
Issue
1
Pages
99-105
Physical description
Contributors
author
author
References
Document Type
REVIEW
Publication order reference
S. Shimohama, Department of Neurology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyoku, Kyoto 606-8507, Japan
Identifiers
YADDA identifier
bwmeta1.element.element-from-psjc-979112f6-ed1e-39de-b0d8-86859611fe02
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.